---
title: "Arrowhead (ARWR) Q2 2026 Earnings Transcript"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285741896.md"
description: "The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
datetime: "2026-05-08T14:25:17.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285741896.md)
  - [en](https://longbridge.com/en/news/285741896.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285741896.md)
---

# Arrowhead (ARWR) Q2 2026 Earnings Transcript

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

### Related Stocks

- [ARWR.US](https://longbridge.com/en/quote/ARWR.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [NDAQ.US](https://longbridge.com/en/quote/NDAQ.US.md)

## Related News & Research

- [Insider Selling: Arrowhead Pharmaceuticals (NASDAQ:ARWR) Director Sells 2,970 Shares of Stock](https://longbridge.com/en/news/286489870.md)
- [Full Transcript: Cellectar Biosciences Q1 2026 Earnings Call](https://longbridge.com/en/news/286422585.md)
- [Arrowhead Pharmaceuticals Eyes $4B REDEMPLO Opportunity as RNAi Pipeline Readouts Near](https://longbridge.com/en/news/286388526.md)
- [Artiva says AB-101 plus rituximab posts 71% ACR50 response in refractory RA study](https://longbridge.com/en/news/286959967.md)
- [BUZZ-Street View: Regeneron's melanoma trial setback raises bigger-picture questions](https://longbridge.com/en/news/286769076.md)